Ongoing Clinical Trials for Acute Pancreatitis
There are currently 5 clinical trials investigating new treatments and management strategies for acute pancreatitis. These studies are testing various approaches including nutritional supplements, fluid therapies, cholesterol-lowering medications, and bile acid treatments to prevent complications and recurrence of the condition. Trials are taking place in Denmark, Hungary, Netherlands, and Spain.
Clinical trial locations
- Denmark
- Hungary
- Netherlands
- Spain
Study on Omega-3 Fatty Acids for Reducing Organ Failure and Mortality in Patients with Severe Acute Pancreatitis
This trial is investigating whether early treatment with omega-3 fatty acids can help prevent organ failure and reduce deaths in people with severe forms of the condition. The study is taking place in the Netherlands and Denmark.
Who can participate: Adults aged 18 or older experiencing their first episode of predicted severe pancreatitis are eligible. The diagnosis must have been made within the last 24 hours, with symptoms starting less than 72 hours ago. To qualify, patients must meet at least one severity marker: an APACHE-II score above 7, a Modified Glasgow score above 2, or a CRP level above 150 mg per liter. Participants must be able to understand the study procedures and provide informed consent.
Who cannot participate: The study excludes patients who do not meet the criteria for predicted severe disease, those outside the specified age range, vulnerable populations, and anyone unable to receive omega-3 fatty acids through an intravenous method. People with other medical conditions that would make participation unsafe are also excluded.
What the trial involves: The study tests Omegaven, an intravenous infusion containing omega-3 fatty acids derived from highly refined fish oil, along with glycerol and purified egg phospholipids. Researchers will monitor participants over 180 days to see if this treatment can reduce new organ failure and mortality. The trial also tracks hospital stay length, need for additional medical interventions, and any side effects.
The investigational treatment: Omega-3 fatty acids are being studied for their anti-inflammatory properties, which may help reduce inflammation in the pancreas and protect other organs from damage. The treatment is given directly into the bloodstream through a vein.
Study Comparing Sodium Chloride and Lactated Ringer’s Solution for Patients with Acute Pancreatitis
This Spanish trial compares two different fluid replacement solutions to determine which provides better outcomes for people with the condition. Proper fluid management is crucial in treating pancreatitis, and this study aims to identify the safer and more effective option.
Who can participate: Adults aged 18 or older with a confirmed diagnosis are eligible. The diagnosis requires at least two of three criteria: typical abdominal pain, enzyme levels more than three times the normal limit, or imaging evidence of the condition. Participants must sign an informed consent form.
Who cannot participate: The study excludes people younger than 18 or older than 65, pregnant or breastfeeding women, and those with kidney problems, heart failure, liver disease, or electrolyte imbalances. People who have recently had surgery or are planning surgery soon cannot participate, nor can those already enrolled in another clinical trial.
What the trial involves: Participants receive either normal saline or lactated Ringer’s solution through an intravenous infusion. Both are standard fluid replacement solutions, but they have different compositions. Researchers will monitor patients for 30 days, tracking the severity of the condition and watching for safety concerns like fluid overload, kidney injury, or mineral imbalances in the blood.
The investigational treatments: Normal saline is a simple saltwater solution, while lactated Ringer’s solution contains sodium, potassium, calcium, and lactate. The trial aims to determine if the additional minerals in lactated Ringer’s solution provide better outcomes or if the simpler normal saline is equally effective.
Study on Normal Saline and Lactated Ringer’s Solution for Adults with Acute Pancreatitis
This Hungarian trial also compares normal saline and lactated Ringer’s solution for fluid therapy. Similar to the Spanish study, it seeks to identify which fluid replacement strategy leads to better patient outcomes.
Who can participate: Adults aged 18 or older with a confirmed diagnosis are eligible. The diagnosis requires at least two of the following: typical abdominal pain, enzyme levels more than three times normal, or imaging evidence of pancreatitis. Participants must provide informed consent.
Who cannot participate: People younger than 18 or older than 65 cannot participate. The study also excludes vulnerable populations who cannot make decisions for themselves.
What the trial involves: Patients are randomly assigned to receive either normal saline or lactated Ringer’s solution through intravenous infusion. The medical team determines the specific dosage and frequency based on each patient’s condition. Throughout the trial, doctors closely monitor for signs of fluid overload, kidney issues, and imbalances in blood minerals.
The investigational treatments: Normal saline provides basic hydration, while lactated Ringer’s solution offers a more balanced mix of electrolytes. The trial will help determine if the additional electrolytes make a meaningful difference in treatment outcomes.
Study on Simvastatin for Preventing Recurrent Pancreatitis in Patients
This Spanish trial explores whether simvastatin, a medication commonly used to lower cholesterol, can prevent repeated episodes in people who have already experienced the condition. The study runs for up to 12 months.
Who can participate: Adults aged 18 or older who have had at least two episodes of acute pancreatitis or multiple episodes of chronic pancreatitis are eligible. Participants must provide written consent.
Who cannot participate: The study excludes people with a history of allergic reactions to simvastatin or similar medications, those taking medications that interact negatively with simvastatin, and people with liver or kidney disease. Pregnant or breastfeeding women, people who have recently had a heart attack or stroke, those with uncontrolled diabetes, and anyone already participating in another clinical trial cannot join.
What the trial involves: This is a triple-blind study, meaning neither participants, healthcare providers, nor researchers know who receives the actual medication versus a placebo. Participants take film-coated tablets orally for up to 12 months. Researchers track new episodes, development of complications like diabetes or pancreatic insufficiency, severity of any recurring episodes, and number of hospital visits due to abdominal pain.
The investigational treatment: Simvastatin works by blocking an enzyme that produces cholesterol in the liver. While commonly used for heart disease prevention, researchers believe it may also help prevent recurrent inflammation of the pancreas through its anti-inflammatory effects.
Study on Ursodeoxycholic Acid to Prevent Recurrence of Acute Biliary Pancreatitis in Patients After Gallstone-Related Episode
This Spanish trial tests whether ursodeoxycholic acid can prevent complications after a first episode caused by gallstones. The medication aims to prevent further problems while patients wait for gallbladder removal surgery or for up to one year.
Who can participate: Adults aged 18 or older who have experienced their first episode of gallstone-related pancreatitis are eligible. The diagnosis requires at least two of three conditions: acute upper abdominal pain, enzyme levels more than three times normal, or imaging evidence of the condition. The gallstone cause must be confirmed by imaging tests showing gallstones, tiny stones, or thick bile in the gallbladder. Participants must sign an informed consent form.
Who cannot participate: People who have already had a recurrence of gallstone-related pancreatitis or those who have not had gallbladder removal surgery within one year of their initial episode cannot participate.
What the trial involves: This double-blind study provides participants with ursodeoxycholic acid capsules or placebo. The medication is taken orally according to the prescribed schedule. Researchers monitor participants through regular follow-up visits, checking for new episodes, gallbladder inflammation, or bile duct infections. The study continues until gallbladder removal surgery or for up to one year.
The investigational treatment: Ursodeoxycholic acid is a bile acid that reduces cholesterol production in the liver and dissolves cholesterol in bile. This action may help prevent new gallstone formation and reduce the risk of complications before the gallbladder can be surgically removed.
Summary
The five ongoing clinical trials for acute pancreatitis reflect diverse approaches to managing this painful condition. A notable geographic pattern emerges, with Spain conducting three of the five trials, demonstrating particularly strong research activity in this area. The other trials are distributed across Denmark, Hungary, and the Netherlands.
The research focuses on three main treatment strategies. Two trials compare different fluid replacement solutions, testing whether lactated Ringer’s solution offers advantages over normal saline. One trial investigates omega-3 fatty acids for severe cases, examining whether these anti-inflammatory compounds can prevent organ failure. The remaining two trials explore prevention of recurrent episodes, testing simvastatin and ursodeoxycholic acid respectively.
These trials address different stages and types of the condition. Some focus on immediate treatment of severe cases, while others aim to prevent future episodes in people who have already experienced the condition. The gallstone-related trial specifically targets a common underlying cause, seeking to prevent complications while patients await definitive surgical treatment.
All trials maintain rigorous scientific standards, with most employing blind or double-blind designs to ensure reliable results. Participants interested in joining should carefully review the eligibility criteria and discuss participation with their healthcare providers.
